Enhertu 100mg Injection

Enhertu 100mg Injection contains the active ingredient trastuzumab deruxtecan, a targeted therapy used to treat certain types of breast and gastric cancers. It is used in adult patients with HER2-positive breast cancer or HER2-positive gastric cancer. This medicine is not recommended for individuals under 18 years of age. The standard dosing schedule involves an infusion every 3 weeks, with patients typically receiving the medicine once every three weeks under the supervision of a healthcare professional. Enhertu works by binding to HER2-positive cancer cells and delivering a cytotoxic agent directly into them, which helps destroy the cancer cells while minimising damage to surrounding healthy tissues. The standard dosing involves an infusion every 3 weeks, administered by a healthcare professional in a clinical setting. Patients with HER2-positive breast cancer may be considered for either Enhertu or Kadcyla, as both are used for HER2-positive breast cancer but differ in formulation, mechanism, and clinical outcomes.

Like all medicines, Enhertu may cause side effects. Common adverse reactions can include nausea, vomiting, fatigue, decreased appetite, and infusion-related reactions. More serious side effects may involve lung or heart problems, so regular monitoring is important.

Enhertu 100mg Injection pricing in India varies depending on location and supplier. The price per month may be substantial, making it important for patients to discuss financial assistance programmes with their doctor or pharmacist.

Enhertu Injection is indicated for the treatment of HER2-positive metastatic breast cancer in patients who have already received other anti-HER2 therapies, as well as HER2-positive advanced gastric cancer in patients previously treated with a trastuzumab-based regimen.

Enhertu 100 mg injection uses are Treats HER2-positive breast cancer that is metastatic or unresectable for patients who have had prior anti-HER2 treatments. Effective for HER2-low metastatic breast cancer after prior chemotherapy. Treats HER2-mutated non-small cell lung cancer (NSCLC) that is metastatic or unresectable following prior treatment. Used for HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma after prior trastuzumab-based therapy. For HER2-positive (IHC 3+) metastatic solid tumours when no other satisfactory treatments are available.

Enhertu 100mg Injection works in a targeted way to treat certain cancer cells. It is made up of two main parts: 1. Monoclonal Antibody: This part of the medication specifically attaches to cancer cells that have the HER2 protein on their surface. These are known as HER2-positive cancer cells, which are common in some breast and stomach cancers. 2. DXd (Drug Conjugate): This is the other active component of Enhertu 100 mg Injection. DXd is a powerful substance that can kill cancer cells. Enhertu 100 mg Injection finds and attaches to HER2-positive cancer cells. Once attached, it delivers the DXd directly into these cancer cells. The DXd then works to kill these cells from the inside. This targeted approach helps attack the cancer cells while sparing many healthy cells in the body.

Enhertu 100mg Injection Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them. Serious: Severe allergic reactions (rashes, itching, difficulty in breathing, fever) Common: Nausea (feeling sick), vomiting Tiredness Decreased appetite Blood tests showing decreased red or white blood cells or platelets Hair loss Diarrhoea Constipation Blood tests showing increased levels of the liver enzymes such as transaminases Pain in muscles and bones Weight loss Fever Abdominal (belly) pain Infections of the nose and throat, including flu-like symptoms Headache Blisters in or around your mouth Cough Blood tests showing low blood potassium levels Indigestion Breathing difficulties Swelling of ankles and feet Nosebleed Altered/bad taste in the mouth Infection of the lungs